PharmaCyte Biotech, Inc.
PMCB
$1.50
-$0.14-8.54%
| 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 22.68M | 26.94M | 333.80K | -1.14M | -1.28M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -24.52M | -29.60M | -2.78M | -1.01M | -522.30K |
| Change in Net Operating Assets | -100.80K | -206.10K | 298.80K | 43.80K | -665.30K |
| Cash from Operations | -1.94M | -2.87M | -2.15M | -2.11M | -2.47M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -12.00M | -12.00M | -5.00M | -5.00M | -- |
| Cash from Investing | -12.00M | -12.00M | -5.00M | -5.00M | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 0.00 | 0.00 | 100.00 | 100.00 | 100.00 |
| Repurchase of Common Stock | -3.72M | -2.48M | -28.20M | -31.33M | -34.71M |
| Issuance of Preferred Stock | 0.00 | 0.00 | 35.00M | 35.00M | 35.00M |
| Repurchase of Preferred Stock | -34.93M | -26.94M | -17.51M | -7.99M | -1.35M |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 2.26M | 0.00 | 0.00 | 0.00 |
| Cash from Financing | -38.65M | -27.16M | -10.71M | -4.32M | -1.06M |
| Foreign Exchange rate Adjustments | 1.00K | -700.00 | -400.00 | -5.30K | -9.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -52.59M | -42.03M | -17.86M | -11.43M | -3.54M |
